Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions on Living Cancer Cells.

Brancaccio D, Diana D, Di Maro S, Di Leva FS, Tomassi S, Fattorusso R, Russo L, Scala S, Trotta AM, Portella L, Novellino E, Marinelli L, Carotenuto A.

J Med Chem. 2018 Apr 12;61(7):2910-2923. doi: 10.1021/acs.jmedchem.7b01830. Epub 2018 Mar 19.

PMID:
29522685
2.

Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.

Di Maro S, Di Leva FS, Trotta AM, Brancaccio D, Portella L, Aurilio M, Tomassi S, Messere A, Sementa D, Lastoria S, Carotenuto A, Novellino E, Scala S, Marinelli L.

J Med Chem. 2017 Dec 14;60(23):9641-9652. doi: 10.1021/acs.jmedchem.7b01062. Epub 2017 Nov 20.

PMID:
29125295
3.

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.

Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, Tasaki S, Portella L, Bai Y, Lannin TB, Suri S, Gruber CN, Pratt ED, Kirby BJ, Eisenberger MA, Nanus DM, Saad F, Giannakakou P; TAXYNERGY Investigators.

J Clin Oncol. 2017 Oct 1;35(28):3181-3188. doi: 10.1200/JCO.2017.72.4138. Epub 2017 Jun 20.

4.

A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors.

Santagata S, Portella L, Napolitano M, Greco A, D'Alterio C, Barone MV, Luciano A, Gramanzini M, Auletta L, Arra C, Zannetti A, Scala S.

Sci Rep. 2017 May 31;7(1):2554. doi: 10.1038/s41598-017-02818-6.

5.

Antibodies against Apicomplexa protozoa and absence sarcocysts in heart tissues from horses in southern Brazil.

Portella LP, Cadore GC, Sangioni LA, Pellegrini LF, Fighera R, Ramos F, Vogel FS.

Rev Bras Parasitol Vet. 2017 Jan-Mar;26(1):100-103. doi: 10.1590/S1984-29612016068. Epub 2017 Mar 16.

6.

Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists.

Di Maro S, Trotta AM, Brancaccio D, Di Leva FS, La Pietra V, Ieranò C, Napolitano M, Portella L, D'Alterio C, Siciliano RA, Sementa D, Tomassi S, Carotenuto A, Novellino E, Scala S, Marinelli L.

J Med Chem. 2016 Sep 22;59(18):8369-80. doi: 10.1021/acs.jmedchem.6b00695. Epub 2016 Sep 9.

PMID:
27571038
7.

Horses seropositive for Toxoplasma gondii, Sarcocystis spp. and Neospora spp.: Possible risk factors for infection in Brazil.

Cazarotto CJ, Balzan A, Grosskopf RK, Boito JP, Portella LP, Vogel FF, Fávero JF, de C Cucco D, Biazus AH, Machado G, Da Silva AS.

Microb Pathog. 2016 Oct;99:30-35. doi: 10.1016/j.micpath.2016.07.016. Epub 2016 Jul 27.

PMID:
27475033
8.

DNA extraction methods and multiple sampling to improve molecular diagnosis of Sarcocystis spp. in cattle hearts.

Bräunig P, Portella LP, Cezar AS, Libardoni F, Sangioni LA, Vogel FS, Gonçalves PB.

Parasitol Res. 2016 Oct;115(10):3913-21. doi: 10.1007/s00436-016-5158-3. Epub 2016 Jun 8.

PMID:
27277233
9.

Anthelmintic resistance in gastrointestinal nematodes of beef cattle in the state of Rio Grande do Sul, Brazil.

Ramos F, Portella LP, Rodrigues FS, Reginato CZ, Pötter L, Cezar AS, Sangioni LA, Vogel FSF.

Int J Parasitol Drugs Drug Resist. 2016 Feb 8;6(1):93-101. doi: 10.1016/j.ijpddr.2016.02.002. eCollection 2016 Apr.

10.

CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis.

Ieranò C, Portella L, Lusa S, Salzano G, D'Alterio C, Napolitano M, Buoncervello M, Macchia D, Spada M, Barbieri A, Luciano A, Barone MV, Gabriele L, Caraglia M, Arra C, De Rosa G, Scala S.

Nanoscale. 2016 Apr 14;8(14):7562-71. doi: 10.1039/c5nr06335c.

PMID:
26983756
11.

Intrinsically disordered amphiphilic peptides as potential targets in drug delivery vehicles.

Vincenzi M, Accardo A, Costantini S, Scala S, Portella L, Trotta A, Ronga L, Guillon J, Leone M, Colonna G, Rossi F, Tesauro D.

Mol Biosyst. 2015 Nov;11(11):2925-32. doi: 10.1039/c5mb00358j.

PMID:
26263446
12.

Conformational ensembles explored dynamically from disordered peptides targeting chemokine receptor CXCR4.

Vincenzi M, Costantini S, Scala S, Tesauro D, Accardo A, Leone M, Colonna G, Guillon J, Portella L, Trotta AM, Ronga L, Rossi F.

Int J Mol Sci. 2015 May 28;16(6):12159-73. doi: 10.3390/ijms160612159.

13.

CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not.

Neve Polimeno M, Ierano C, D'Alterio C, Simona Losito N, Napolitano M, Portella L, Scognamiglio G, Tatangelo F, Maria Trotta A, Curley S, Costantini S, Liuzzi R, Izzo F, Scala S.

Cell Mol Immunol. 2015 Jul;12(4):474-82. doi: 10.1038/cmi.2014.102. Epub 2014 Nov 3.

14.

Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.

Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM.

Mol Diagn Ther. 2014 Aug;18(4):389-402. doi: 10.1007/s40291-014-0101-8.

15.

Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P.

Cancer Res. 2014 Apr 15;74(8):2270-2282. doi: 10.1158/0008-5472.CAN-13-2876. Epub 2014 Feb 20.

16.

Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases.

Portella L, Vitale R, De Luca S, D'Alterio C, Ieranò C, Napolitano M, Riccio A, Polimeno MN, Monfregola L, Barbieri A, Luciano A, Ciarmiello A, Arra C, Castello G, Amodeo P, Scala S.

PLoS One. 2013 Sep 13;8(9):e74548. doi: 10.1371/journal.pone.0074548. eCollection 2013.

17.

Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.

Polimeno M, Napolitano M, Costantini S, Portella L, Esposito A, Capone F, Guerriero E, Trotta A, Zanotta S, Pucci L, Longo N, Perdonà S, Pignata S, Castello G, Scala S.

BJU Int. 2013 Sep;112(5):686-96. doi: 10.1111/bju.12068. Epub 2013 Mar 15.

18.

The N-terminal region of CXCL11 as structural template for CXCR3 molecular recognition: synthesis, conformational analysis, and binding studies.

Palladino P, Portella L, Colonna G, Raucci R, Saviano G, Rossi F, Napolitano M, Scala S, Castello G, Costantini S.

Chem Biol Drug Des. 2012 Aug;80(2):254-65. doi: 10.1111/j.1747-0285.2012.01397.x. Epub 2012 May 23.

PMID:
22531000
19.

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

D' Alterio C, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G, Scala S.

Curr Cancer Drug Targets. 2012 Jul;12(6):693-702.

PMID:
22463589
20.

Inhibition of stromal CXCR4 impairs development of lung metastases.

D'Alterio C, Barbieri A, Portella L, Palma G, Polimeno M, Riccio A, Ieranò C, Franco R, Scognamiglio G, Bryce J, Luciano A, Rea D, Arra C, Scala S.

Cancer Immunol Immunother. 2012 Oct;61(10):1713-20. Epub 2012 Mar 8.

21.

Differential role of CD133 and CXCR4 in renal cell carcinoma.

D'Alterio C, Cindolo L, Portella L, Polimeno M, Consales C, Riccio A, Cioffi M, Franco R, Chiodini P, Cartenì G, Mirone V, Longo N, Marra L, Perdonà S, Claudio L, Mascolo M, Staibano S, Falsaperla M, Puglisi M, Martignoni G, Ficarra V, Castello G, Scala S.

Cell Cycle. 2010 Nov 15;9(22):4492-4500.

PMID:
21127401
22.

Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.

D'Alterio C, Consales C, Polimeno M, Franco R, Cindolo L, Portella L, Cioffi M, Calemma R, Marra L, Claudio L, Perdonà S, Pignata S, Facchini G, Cartenì G, Longo N, Pucci L, Ottaiano A, Costantini S, Castello G, Scala S.

Curr Cancer Drug Targets. 2010 Nov;10(7):772-81.

PMID:
20578990
23.

A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration.

Ierano C, Giuliano P, D'Alterio C, Cioffi M, Mettivier V, Portella L, Napolitano M, Barbieri A, Arra C, Liguori G, Franco R, Palmieri G, Rozzo C, Pacelli R, Castello G, Scala S.

Cell Cycle. 2009 Apr 15;8(8):1228-37. Epub 2009 Apr 23.

PMID:
19305148
24.

Reading and writing: psychoanalytical treatment in a case of paranoia.

Freire JM, de Cerqueira Leite AC, Bueno DS, Portella LB, Ribes SI, Assadi TC, Colucci VL, Pereira ME.

Am J Psychoanal. 2005 Sep;65(3):219-38.

PMID:
16142527

Supplemental Content

Loading ...
Support Center